NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it has regained compliance with Nasdaq's Minimum Bid Price Requirement, closing a matter that had threatened the company's listing on the Nasdaq Capital Market. The company received a notification letter from Nasdaq's Listing Qualifications Department confirming that it now meets Marketplace Rule 5550(a)(2), which requires a minimum closing bid price of $1 per share for continued listing.
The compliance issue began on May 6, 2025, when NeuroOne first received a notice from Nasdaq stating that its common stock had traded below the $1 threshold for 30 consecutive business days. After being granted a 180-day extension on November 4, 2025, the company regained compliance by effecting a 1-for-6 reverse stock split that became effective on April 15, 2026. The split-adjusted shares began trading on April 16, 2026, under the same symbol "NMTC" but with a new CUSIP number (64130M308).
For NeuroOne, maintaining Nasdaq listing is crucial for visibility among institutional investors and access to capital markets. The reverse stock split was a necessary step to boost the per-share price above the minimum requirement, a common strategy among small-cap companies facing delisting. However, reverse splits can sometimes carry negative connotations, as they reduce the number of outstanding shares and may signal financial distress. In this case, the company successfully met the regulatory requirement without further intervention.
NeuroOne is a medical technology company focused on improving surgical outcomes for patients with neurological disorders. Its product portfolio includes four FDA-cleared families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These minimally invasive, high-definition electrode platforms are designed to reduce hospitalizations and surgical procedures while lowering costs. Additionally, the company is pursuing research and development in drug delivery, basivertebral nerve ablation, and spinal cord stimulation.
The implications of this compliance restoration are significant for NeuroOne's stakeholders. For investors, the resolution removes the uncertainty of potential delisting, which could have led to reduced liquidity and loss of investor confidence. For the company, continued Nasdaq listing supports its ability to raise capital for ongoing R&D and commercialization efforts. In the broader context, NeuroOne's technologies address critical needs in neurosurgery, offering diagnostic and therapeutic functions that could improve patient outcomes. The company's ability to maintain its listing ensures that these innovations remain accessible to the market.
As NeuroOne moves forward, it will need to sustain compliance with Nasdaq's continued listing requirements, including maintaining a minimum bid price above $1. The reverse stock split provides a temporary fix, but long-term value creation through revenue growth and product adoption will be essential to avoid future compliance issues. The company's focus on expanding its product pipeline and commercializing existing technologies will be key to its success.
